{"id":52350,"date":"2022-12-27T14:02:25","date_gmt":"2022-12-27T13:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/"},"modified":"2022-12-27T14:02:25","modified_gmt":"2022-12-27T13:02:25","slug":"novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/","title":{"rendered":"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer"},"content":{"rendered":"
\n

\nJudy Ashworth, MD, Chief Medical Officer of Novadip Biosciences SA<\/i>\n<\/p>\n

MONT SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–#Belgium<\/a>–Novadip Biosciences SA (\u201cNovadip\u201d or \u201cthe Company\u201d), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company. Dr. Ashworth brings deep experience and strong managerial skills in drug development and operations.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are pleased to welcome Dr. Judy Ashworth to our executive management team,\u201d said Denis Dufrane, MD, PhD, Chief Executive Officer of Novadip. \u201cDr. Ashworth has a tremendous amount of experience in clinical development. She will help guide and accelerate our clinical development program, including our upcoming Type C meeting with FDA to discuss the next development step for one of our lead assets, NVD-003.\u201d\n<\/p>\n

\nDr. Ashworth is currently Senior Vice President at Pinney Associates, Inc., where she supports clients\u2019 clinical development programs across a range of indications. Dr. Ashworth also serves as the Chief Medical Officer for Harm Reduction Therapeutics, a nonprofit pharmaceutical company developing a low-cost naloxone available product for the OTC market to reduce opioid overdose deaths. Dr. Ashworth received her bachelor\u2019s degree in Biology from the University of California Santa Barbara<\/a> and her medical degree from the University of California Los Angeles<\/a>.\n<\/p>\n

\n\u201cI am elated to join the Novadip team to help advance the clinical development of Novadip\u2019s tissue regeneration product pipeline,\u201d said Dr. Ashworth, MD, Chief Medical Officer of Novadip. \u201cThe data and patient outcomes generated to date from both clinical studies and compassionate use truly demonstrate the potential clinical utility of this technology for patients with critical size bone defects and non-healing fractures.\n<\/p>\n

\nNovadip is developing NVD-003, an autologous therapy derived from adipose stem cells as a potential single treatment to save limbs and restore mobility\u200b in patients with congenital pseudarthrosis of the tibia (CPT), a rare pediatric bone condition. NVD-003 has received orphan drug and rare pediatric disease designations from the US FDA. If NVD-003 is approved by the FDA, Novadip is eligible to receive a priority review voucher that could provide more than $100 million revenue. The Company is also developing an allogeneic \u201coff-the-shelf\u201d therapeutic, NVD-X3, to provide accelerated, durable bone union in common orthopedic conditions such as spinal fusion and non-healing fractures. Both investigational products are derived from Novadip\u2019s 3M\u00b3 platform, a 3-dimensional, extracellular matrix that utilizes adipose-derived stem cells to deliver highly specific growth factors and miRNAs to mimic the physiology of natural tissue healing.\n<\/p>\n

\nAbout Novadip Biosciences<\/b>\n<\/p>\n

\nNovadip Biosciences SA is a clinical stage company developing best in class tissue regeneration therapies to elevate the standard of care for critical size bone defects, common orthopedic conditions, and cancer. Its unique 3M\u00b3 tissue regeneration technology platform has the potential to generate an array of product candidates to address hard and soft tissue reconstruction for patients with limited or no treatment options. Co-Founded in 2013 by Denis Dufrane, MD, PhD, Novadip is headquartered in Mont Saint-Guibert, Belgium. For more information, visit http:\/\/www.novadip.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Inquiries:<\/b>
Anna Army
\n
LaVoieHealthScience
\n
(617) 351-0246
\n
aarmy@lavoiehealthscience.com<\/a><\/p>\n

Investor Inquiries:<\/b>
Gemma Bakx
\n
LaVoieHealthScience
\n
(917) 439-5771
\n
gbakx@lavoiehealthscience.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Judy Ashworth, MD, Chief Medical Officer of Novadip Biosciences SA MONT SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–#Belgium–Novadip Biosciences SA (\u201cNovadip\u201d or \u201cthe Company\u201d), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company. Dr. Ashworth brings … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52350","6":"format-standard","7":"category-industry"},"yoast_head":"\nNovadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Judy Ashworth, MD, Chief Medical Officer of Novadip Biosciences SA MONT SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–#Belgium–Novadip Biosciences SA (\u201cNovadip\u201d or \u201cthe Company\u201d), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company. Dr. Ashworth brings ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-27T13:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221227005137\/en\/1672972\/21\/Judy_on_white_1320_Med_cropped.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer\",\"datePublished\":\"2022-12-27T13:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/\"},\"wordCount\":534,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221227005137\\\/en\\\/1672972\\\/21\\\/Judy_on_white_1320_Med_cropped.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/\",\"name\":\"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221227005137\\\/en\\\/1672972\\\/21\\\/Judy_on_white_1320_Med_cropped.jpg\",\"datePublished\":\"2022-12-27T13:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221227005137\\\/en\\\/1672972\\\/21\\\/Judy_on_white_1320_Med_cropped.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221227005137\\\/en\\\/1672972\\\/21\\\/Judy_on_white_1320_Med_cropped.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/","og_locale":"en_US","og_type":"article","og_title":"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer - Pharma Trend","og_description":"Judy Ashworth, MD, Chief Medical Officer of Novadip Biosciences SA MONT SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–#Belgium–Novadip Biosciences SA (\u201cNovadip\u201d or \u201cthe Company\u201d), a clinical stage company developing treatments to regenerate impaired tissue in patients with significant unmet medical needs, today announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company. Dr. Ashworth brings ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-27T13:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221227005137\/en\/1672972\/21\/Judy_on_white_1320_Med_cropped.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer","datePublished":"2022-12-27T13:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/"},"wordCount":534,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221227005137\/en\/1672972\/21\/Judy_on_white_1320_Med_cropped.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/","url":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/","name":"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221227005137\/en\/1672972\/21\/Judy_on_white_1320_Med_cropped.jpg","datePublished":"2022-12-27T13:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221227005137\/en\/1672972\/21\/Judy_on_white_1320_Med_cropped.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221227005137\/en\/1672972\/21\/Judy_on_white_1320_Med_cropped.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/novadip-biosciences-sa-appoints-judy-ashworth-md-as-chief-medical-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Novadip Biosciences SA Appoints Judy Ashworth, MD, as Chief Medical Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52350"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52350\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}